Amgen Greater China Ltd., a wholly owned subsidiary ofAmgen Inc., announced Friday that it officially opened its HongKong office to provide promotional and technical support formedical product sales in China.
Amgen (NASDAQ:AMGN) of Thousand Oaks, Calif., has beenselling Epogen, its Epoetin alfa, to stimulate production of redblood cells in patients who are suffering chronic renal failure inChina since January.
Amgen's Neupogen, which stimulates production of infection-fighting white cells called neutrophils, is undergoing clinicalverification at China's leading oncology centers as an adjunct tochemotherapy.
"Amgen is the only biotechnology company actively operatingin the People's Republic of China," said Lowell Sears, thecompany's senior vice president for Asia-Pacific. Amgenreceived marketing approval for Epogen in China in September1992 and has conducted symposia on its benefits in Beijing,Shanghai and Guangzhou.
Albert Fan, general manager of Amgen Greater China Ltd., saidthe subsidiary was established to strengthen the company'sties to the medical community in China.
Neupogen has also received the prestigious European, British,French and Belgian Prix Gallen for new pharmaceuticalproducts that make the most significant contributions topatient care in terms of efficacy, safety and innovation. --Nancy Garcia
(c) 1997 American Health Consultants. All rights reserved.